Stock Events

Stock Events

Enanta Pharmaceuticals 

$14.08
15
+$0.06+0.43% Friday 20:00

Statistics

Day High
14.15
Day Low
14.07
52W High
17.15
52W Low
7.05
Volume
8,135
Avg. Volume
-
Mkt Cap
410.09M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

16NovExpected
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Next
-1.15
-0.9
-0.66
-0.42
Expected EPS
-0.769216
Actual EPS
N/A

Financials

-125.36%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
65.32MRevenue
-81.89MNet Income

Analyst Ratings

20.00Average Price Target
The highest estimate is 20.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ENTA. It's not an investment recommendation.
AT&T
6
T
Microsoft
5
MSFT
Johnson & Johnson
5
JNJ
PepsiCo
5
PEP

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Gilead Sciences
GILD
Mkt Cap180.64B
Gilead Sciences is a direct competitor in the antiviral drug market, particularly in treatments for hepatitis C, where Enanta and Gilead have had collaborations but also compete.
Abbvie
ABBV
Mkt Cap451.46B
AbbVie competes with Enanta in the hepatitis C virus (HCV) treatment market, especially since Enanta has developed drugs that are part of AbbVie's HCV treatment regimens.
Merck
MRK
Mkt Cap366B
Merck & Co. is involved in developing treatments for infectious diseases, including hepatitis C, directly competing with Enanta's drug development focus.
Vertex Pharmaceuticals
VRTX
Mkt Cap137.3B
Vertex Pharmaceuticals competes with Enanta in the development of treatments for cystic fibrosis, as both companies are involved in creating therapies for genetic and chronic diseases.
Bristol-Myers Squibb
BMY
Mkt Cap136B
Bristol Myers Squibb competes in the antiviral space, particularly in hepatitis B and C, areas where Enanta Pharmaceuticals has significant interest and development efforts.
Pfizer
PFE
Mkt Cap159.36B
Pfizer competes across a broad range of therapeutic areas, including antiviral drugs, which puts it in competition with Enanta Pharmaceuticals in the infectious disease market.
Johnson & Johnson
JNJ
Mkt Cap645.95B
Johnson & Johnson, through its pharmaceutical division Janssen, competes with Enanta in the development of treatments for infectious diseases, including hepatitis C.
GSK
GSK
Mkt Cap101.78B
GlaxoSmithKline competes with Enanta in the development of vaccines and treatments for viral infections, including hepatitis and respiratory diseases.
Arrowhead Pharmaceuticals
ARWR
Mkt Cap11.99B
Arrowhead Pharmaceuticals is involved in developing RNAi therapeutics for chronic diseases, including hepatitis B, making it a competitor in the viral infection treatment market.

About

Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.
Show more...
CEO
Jay R. Luly
Employees
120
Country
United States
ISIN
US29251M1062
WKN
000A1T7BJ

Listings

MU
DE
9EP.MU
STU
DE
9EP.STU
F
DE
9EP.F
XNAS
US
ENTA

0 Comments

Share your thoughts

FAQ

What is Enanta Pharmaceuticals stock price today?▼
The current price of ENTA is $14.08 USD — it has increased by +0.43% in the past 24 hours. Watch Enanta Pharmaceuticals stock price performance more closely on the chart.
What is Enanta Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Enanta Pharmaceuticals stocks are traded under the ticker ENTA.
Is Enanta Pharmaceuticals stock price growing?▼
ENTA stock has risen by +3.53% compared to the previous week, the month change is a +6.51% rise, over the last year Enanta Pharmaceuticals has showed a +59.1% increase.
What is Enanta Pharmaceuticals market cap?▼
Today Enanta Pharmaceuticals has the market capitalization of 410.09M
When is the next Enanta Pharmaceuticals earnings date?▼
Enanta Pharmaceuticals is going to release the next earnings report on November 16, 2026.
What were Enanta Pharmaceuticals earnings last quarter?▼
ENTA earnings for the last quarter are -0.67 USD per share, whereas the estimation was -0.51 USD resulting in a -31.5% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Enanta Pharmaceuticals revenue for the last year?▼
Enanta Pharmaceuticals revenue for the last year amounts to 65.32M USD.
What is Enanta Pharmaceuticals net income for the last year?▼
ENTA net income for the last year is -81.89M USD.
How many employees does Enanta Pharmaceuticals have?▼
As of September 05, 2026, the company has 120 employees.
In which sector is Enanta Pharmaceuticals located?▼
Enanta Pharmaceuticals operates in the Health & Wellness sector.
When did Enanta Pharmaceuticals complete a stock split?▼
Enanta Pharmaceuticals has not had any recent stock splits.
Where is Enanta Pharmaceuticals headquartered?▼
Enanta Pharmaceuticals is headquartered in WATERTOWN, United States.